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There is a growing interest in the use of metal-based chemotherapeutic agents to fight 
different types of cancers [1]. Among the most commonly used family of organometallic 
compounds derived from platinum, Cisplatin (CisPt) is the lead compound for the treatment 
of various cancers including lung, testis, gastric, breast, etc. Nevertheless, beside its 
recognized therapeutic effects, side effects such as gastric toxicity and acute kidney failure 
were observed during treatment with CisPt, thereby limiting its clinical use. Other compounds 
are currently studied and among them, Ruthenium (Ru) complexes have gained more 
importance for their lower toxicity and aggressive effect on healthy tissues than CisPt. Ru-
complexes are also more resorbed and excreted [2]. Numerous studies focused on the 
mechanisms of action of Ruthenium compounds to fight cancer, including antioxidant or pro-
oxidant activity.  
During inflammation, activation and infiltration of neutrophils contribute to oxidant 
stress playing a crucial role in tumor development. Likewise, the degranulation of neutrophil 
causes the release of myeloperoxidase (MPO), which reacts with H2O2 to catalyze redox 
reactions. A therapeutic target to control inflammation is the modulation of oxidant enzymes 
and cells involved in radical species production and redox reactions.     
Because Ruthenium compounds can easily enter into cancer cells, a series of newly 
synthesized Ru(II)-complexes were used for this purpose. They were first tested for their 
radical scavenging activities using ABTS and 1,1-diphenyl-2-picrylhydrazyl (DPPH) assays.  
Amongst them, compound 1 (LD0436) and compound 2 (LD04037) were then studied 
for their ability to modulate the reactive oxygen species (ROS) production by inflammatory 
cells like human promyelocytic leukemia cell line (HL 60) and neutrophils (PMN) using 
fluorescence, chemiluminescence (CL) and electron spin resonance (ESR) techniques. The 
toxicity of those Ru-complexes against HL-60 and neutrophils was checked using Trypan 
blue exclusion assay.  
Altogether, CL and ESR findings indicate that both complexes 1 (LD0436) and 2 
(LD0437) exhibit a dose-dependent inhibitory activity compared to CisPt, gallic acid, 
curcumin and quercetin, which were taken as reference molecules in the various systems 
investigated. Similarly, the Ru(II) complexes tested also display an antioxidant profile on the 
substrate oxidation catalyzed by peroxidase such as MPO mainly involved in acute and 
chronic inflammatory situations. 
  
1: (RuCl(p-cymene)(S2C.IDip)]+(PF6)–], 2: (RuCl(p-cymene)(S2C.ICy)]+(PF6)–] 
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